Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: A prospective, comparative, observational study

Reproductive Toxicology

Volumn 43, Issue , 2014, Pages 78-84

  Diav Citrin, Orna ^a,b   Otcheretianski Volodarsky, Anna ^c   Shechtman, Svetlana ^a   Ornoy, Asher ^a,b  

^a MINISTRY OF HEALTH   (Israel)

^b HEBREW UNIVERSITY   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Adalimumab; Anti TNF ; Autoimmune diseases; Congenital anomalies; Etanercept; Infliximab; Pregnancy

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ANKYLOSING SPONDYLITIS; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; BEHCET DISEASE; BIRTH WEIGHT; COHORT ANALYSIS; COMPARATIVE STUDY; CONGENITAL MALFORMATION; CONTROLLED STUDY; CORPUS CALLOSUM AGENESIS; CROHN DISEASE; DISEASE ASSOCIATION; DOWN SYNDROME; DRUG SAFETY; FEMALE; FIRST TRIMESTER PREGNANCY; FOLLOW UP; GESTATIONAL AGE; HUMAN; ISRAEL; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; OSTEOGENESIS IMPERFECTA; PREGNANCY OUTCOME; PREGNANCY TERMINATION; PRENATAL DRUG EXPOSURE; PROSPECTIVE STUDY; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SPONTANEOUS ABORTION; SYNDROME VATER; TERATOGENESIS; TOXICITY TESTING; TREATMENT DURATION; ULCERATIVE COLITIS;

ADALIMUMAB; ANTI-TNF-Α; AUTOIMMUNE DISEASES; CONGENITAL ANOMALIES; ETANERCEPT; INFLIXIMAB; PREGNANCY;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS; BEHCET SYNDROME; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HUMANS; IMMUNOGLOBULIN G; MATERNAL-FETAL EXCHANGE; PREGNANCY; PREGNANCY OUTCOME; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84890163674     PISSN: 08906238     EISSN: 18731708     Source Type: Journal    
DOI: 10.1016/j.reprotox.2013.11.004     Document Type: Article

References (36)

1. Treacy G. Using an analogous monoclonal antibody to evaluate the reproductive and chronic toxicity potential for the humanized anti-TNF alpha monoclonal antibody. Hum Exp Toxicol 2000, 19:226-228.
2. Vasiliauskas E.A., Church J.A., Silverman N., Barry M., Targan S.R., Dubinsky M.C. Case report: evidence for transplacental trasfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 2006, 4:1255-1258.
3. Zelinkova Z., de Haar C., de Ridder L., Pierik M.J., Kuipers E.J., Peppelenbosch M.P., et al. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther 2011, 33:1053-1058.
4. Murashima A., Watanabe N., Ozawa N., Saito H., Yamaguchi K. Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breastmilk and the infant's serum [Letter]. Ann Rheum Dis 2009, 68:1793-1794.
5. Mahadevan U., Wolf D.C., Dubinsky M., Cortot A., Lee S.D., Siegel C.A., et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013, 11:286-292.
6. Lee H., Kimko H.C., Rogge M., Wang D., Nestorov I., Peck C.C. Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. Clin Pharmacol Ther 2003, 73:348-365.
7. Ternant D., Aubourg A., Magdelaine-Beuzelin C., Degenne D., Watier H., Picon L., et al. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit 2008, 30:523-529.
8. Weisman M.H., Moreland L.W., Furst D.E., Weinblatt M.E., Keystone E.C., Paulus H.E., et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther 2003, 25:1700-1721.
9. Djokanovic N., Klieger-Grossman C., Pupco A., Koren G. Safety of infliximab use during pregnancy. Reprod Toxicol 2011, 32:93-97.
10. Chambers C.D., Johnson D.L. Emerging data on the use of anti-tumor necrosis factor-alpha medications in pregnancy. Birth Defects Res A Clin Mol Teratol 2012, 94:607-611.
11. Carter J.D., Valeriano J., Vasey F.B. Tumor necrosis factor-alpha inhibition and VATER association: a causal relationship. J Rheumatol 2006, 33:1014-1017.
12. Carter J.D., Ladhani A., Ricca L.R., Valeriano J., Vasey F.B. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol 2009, 36:635-641.
13. Koren G., Inoue M. Do tumor necrosis factor inhibitors cause malformations in humans? [editorial]. J Rhematol 2009, 36:465-466.
14. Winger E.E., Reed J.L. Was risk properly assessed in Carter, et al's safety assessment of tumor necrosis factor antagonists during pregnancy? [Letter]. J Rheumatol 2009, 36:2122.
15. Katz J.A., Antoni C., Keenan G.F., Smith D.E., Jacobs S.J., Lichtenstein G.R. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 2004, 99:2385-2392.
16. Chambers C.D., Johnson D.L., Jones K.L. Pregnancy outcome in women exposed to anti-TNF-alpha medications: the OTIS rheumatoid arthritis in pregnancy study [abstract]. Arthritis Rheumat 2004, 50:S479-S480.
17. Mahadevan U., Kane S., Sandborn W.J., Cohen R.D., Hanson K., Terdiman J.P., et al. International infliximab use during pregnancy for the induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther 2005, 21:733-738.
18. Lichtenstein G.R., Feagan B.G., Cohen R.D., Salzberg B.A., Diamond R.H., Chen D.M., et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006, 4:621-630.
19. Lichtenstein G.R., Feagan B.G., Cohen R.D., Salzberg B.A., Diamond R.H., Price S., et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroeneterol 2012, 107:1409-1422.
20. Roux C.H., Brocq O., Breuil V., Albert C., Euller-Ziegler L. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy. Rheumatoloy (Oxford) 2007, 46:695-698.
21. Berthelot J.M., De Bandt M., Goupille P., Solau-Gervais E., Lioté F., Goeb V., et al. Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. Joint Bone Spine 2009, 76:28-34.
22. Rump J.A., Schönborn H. Conception and course of eight pregnancies in five women on TNF blocker etanercept treatment [German]. Z Rheumatol 2010, 69:903-909.
23. Verstappen S.M., King Y., Watson J.D., Symmons D.P., Hyrich K.L. Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011, 70:823-826. BSRBR Control Centre Consortium, BSR Biologics Register.
24. Schnitzler F., Fidder H., Ferrante M., Ballet V., Noman M., Van Assche G., et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis 2011, 17:1846-1854.
25. Weber-Schoendorfer C., Fritzsche J., Schaefer C. Pregnancy outcome in women exposed to adalimumab or infliximab: the experience of the Berlin Institute for Clinical Teratology and Drug Risk Assessment [abstract]. Reprod Toxicol 2011, 31:267-268.
26. Hultzsch S., Weber-Scoendorfer C., Schaefer C. Pregnancy outcomes after exposure to etanercept [abstract]. Reprod Toxicol 2011, 31:260.
27. Chambers C.D., Johnson D.L., Jones K.L., Luo Y., Xu R., Jimenez J.L., et al. Pregnancy outcomes in women exposed to adalimumab for the treatment of rheumatoid arthritis: an update on the OTIS Autoimmune Diseases in Pregnancy Project [abstract]. Birth Defects Res A Clin Mol Teratol 2012, 94:325.
28. Viktil K.K., England A., Furi K. Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150,000 pregnant women and expectant fathers. Scand J Rheumatol 2012, 41:196-201.
29. Cornish J., Tan E., Teare J., Teoh T.G., Rai R., Clark S.K., et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut 2007, 56:830-837.
30. Mahadevan U., Dandborn W.J., Li D.K., Hakimian S., Kane S., Corley D.A. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology 2007, 133:1106-1112.
31. Bortoli A., Pedersen N., Duricova D., D'Inca R., Gionchetti P., Panelli M.R., et al. Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003-2006. Aliment Pharmacol Ther 2011, 34:724-734.
32. Reed S.D., Vollan T.A., Svec M.A. Pregnancy outcomes in women with rheumatoid arthritis in Washington State. Matern Child Health J 2006, 10:361-366.
33. Nørgaard M., Larsson H., Pedersen L., Granath F., Askling J., Kieler H., et al. Rheumatoid arthritis and birth outcomes: a Danish and Swedish nationwide prevalence study. J Intern Med 2012, 268:329-337.
34. de Man Y.A., Hazes J.M., van der Heide H., Willemsen S.P., de Groot C.J., Steegers E.A., et al. Association of higher rheumatoid arthritis disease activity during pregnancy with lower birth weight: results of a national prospective study. Arthritis Rheum 2009, 60:3196-3206.
35. Bowden A.P., Barrett J.H., Fallow W., Silman A.J. Women with inflammatory polyarthritis have babies of lower birth weight. J Rheumatol 2001, 28:355-359.
36. Pirson Y., Van Lierde M., Ghysen J., Squifflet J.P., Alexandre G.P., van Ypersele de Strihou C. Retardation of fetal growth in patients receiving immunosuppressive therapy [Letter]. N Engl J Med 1985, 313:328.